twelks,
I am implying no such impropriety. The patent applications in question are public knowledge, having been published by the patent office.
If the genomic industry perceived that there was value in the intellectual property contained in the patents, there would be potential bidders within the industry for that property. The market, in it's infinite wisdom, upon becoming aware of that interest would immediately set a value on that property and reflect an estimate of that value in the pps.
It is how the market has behaved since day one. While it may be possible for a single company to keep a negotiation quiet for a limited period of time (almost never happens), if there were more than one company interested it would be known instantly. To suggest that the technology of the company is both groundbreaking but limited to only one interested party is a stretch that can only be presented as a rationalization for the present state of morbidity.
regards,
frog
regards,
frog
News 
Market Data 
Discover 
AI
